Unmet Need in Essential Thrombocythemia and Polycythemia Vera

被引：3
|
作者：
Kishtagari, Ashwin [1 ]
Gerds, Aaron T. [1 ]
机构：
[1] Cleveland Clin, Leukemia & Myeloid Disorders Program, Taussig Canc Inst, 9500 Euclid Ave,CA60, Cleveland, OH 44120 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 02期
关键词：
Myeloproliferative neoplasms; MPN; ET; PV; Bomedemstat; IFN-alpha; Idasanutlin; Givinostat;
D O I：
10.1016/j.hoc.2021.01.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification. © 2021 Elsevier Inc.
引用
收藏
页码：295 / 303
页数：9
相关论文
共 50 条
  • [41] Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea
    Sever, Matjaz
    Newberry, Kate J.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2685 - 2690
  • [42] Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
    Tefferi, Ayalew
    Barbui, Tiziano
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1599 - 1613
  • [43] Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
    Tefferi, Ayalew
    Barbui, Tiziano
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (01) : 95 - 108
  • [44] Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
    Tefferi, Ayalew
    Barbui, Tiziano
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : 133 - 143
  • [45] Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions
    Hannah Goulart
    John Mascarenhas
    Douglas Tremblay
    Annals of Hematology, 2022, 101 : 935 - 951
  • [46] Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions
    Goulart, Hannah
    Mascarenhas, John
    Tremblay, Douglas
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 935 - 951
  • [47] Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia
    Pemmaraju, Naveen
    Gerds, Aaron T.
    Yu, Jingbo
    Parasuraman, Shreekant
    Shah, Anne
    Xi, Ann
    Kumar, Shambhavi
    Scherber, Robyn M.
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2022, 115
  • [48] Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
    Sacco, Monica
    Ranalli, Paola
    Lancellotti, Stefano
    Petrucci, Giovanna
    Dragani, Alfredo
    Rocca, Bianca
    De Cristofaro, Raimondo
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (03) : 413 - 421
  • [49] Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera
    Rottenstreich, A.
    Kleinstern, G.
    Krichevsky, S.
    Varon, D.
    Lavie, D.
    Kalish, Y.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 41 : 49 - 54
  • [50] Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
    Tremblay, Douglas
    Kosiorek, Heidi E.
    Dueck, Amylou C.
    Hoffman, Ronald
    FRONTIERS IN ONCOLOGY, 2021, 10
12345